← Every applicant
Regcon Holdings FDA Approvals
28 new drug approvals and 0 device clearances on file. This applicant is not matched to a listed company.
Newest first
A new drug approval is an original application; a 510(k) is a device shown equivalent to one already sold.
| Product |
|---|
| ILOPROSTNew drugJul 10, 2026SOLUTION, INHALATION |
| BRIVARACETAMNew drugFeb 23, 2026SOLUTION, ORAL |
| LACOSAMIDENew drugJan 29, 2026SOLUTION, ORAL |
| RIVAROXABANNew drugAug 11, 2025TABLET, ORAL |
| FAMOTIDINENew drugMar 25, 2025TABLET, ORAL |
| VARENICLINE TARTRATENew drugOct 29, 2024TABLET, ORAL |
| CETIRIZINE HYDROCHLORIDENew drugOct 3, 2024TABLET, ORAL |
| CHLORPROMAZINE HYDROCHLORIDENew drugSep 24, 2024INJECTABLE, INJECTION |
| THIOTEPANew drugAug 20, 2024POWDER, INTRACAVITARY, INTRAVENOUS, INTRAVESICAL |
| LOFEXIDINE HYDROCHLORIDENew drugAug 20, 2024TABLET, ORAL |
| PREGABALINNew drugMay 17, 2024CAPSULE, ORAL |
| CEFTRIAXONENew drugJan 12, 2024INJECTABLE, INTRAMUSCULAR, INTRAVENOUS |
| CARBIDOPANew drugDec 11, 2023TABLET, ORAL |
| AMOXICILLIN AND CLAVULANATE POTASSIUMNew drugSep 15, 2023TABLET, ORAL |
| AMOXICILLIN AND CLAVULANATE POTASSIUMNew drugSep 15, 2023TABLET, ORAL |
| NEBIVOLOL HYDROCHLORIDENew drugMar 30, 2023TABLET, ORAL |
| BRIMONIDINE TARTRATE AND TIMOLOL MALEATENew drugOct 4, 2022SOLUTION/DROPS, OPHTHALMIC |
| OXYBUTYNIN CHLORIDENew drugJul 14, 2022TABLET, ORAL |
| ELETRIPTAN HYDROBROMIDENew drugJul 13, 2022TABLET, ORAL |
| MINOCYCLINE HYDROCHLORIDENew drugMay 27, 2022TABLET, ORAL |
| LACOSAMIDENew drugApr 7, 2022SOLUTION, INTRAVENOUS |
| AMINOCAPROIC ACIDNew drugMar 23, 2022SOLUTION, ORAL |
| LACOSAMIDENew drugMar 17, 2022TABLET, ORAL |
| ACETYLCYSTEINENew drugFeb 23, 2022INJECTABLE, INTRAVENOUS |
| THIOTEPANew drugDec 8, 2021INJECTABLE, INJECTION |
| NEOSTIGMINE METHYLSULFATENew drugOct 1, 2021SOLUTION, INTRAVENOUS |
| BACLOFENNew drugJul 16, 2021TABLET, ORAL |
| SUMATRIPTANNew drugFeb 17, 2021SPRAY, NASAL |